Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].

Bulletin du cancer - 1 Mar 2007

Dieras Véronique, Vincent-Salomon Anne, Degeorges Armelle, Beuzeboc Philippe, Mignot Laurent, de Cremoux Patricia

Abstract excerpt

The detection of overexpression of human epidermal growth factor receptor 2 (HER2) in some breast cancer tumors has led to the development of a targeted treatment that is tumor selective, effective at extending life expectancy in the patients with advanced or early breast cancers. Trastuzumab (Herceptin), a humanized monoclonal antibody to HER2 is indicated for patients whose tumor demonstrates an amplified copy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cyclin-Dependent Kinase Inhibitor p27

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, erbB-2

Share to Proto-Oncogene Proteins c-akt

Share to PTEN Phosphohydrolase

Share to Receptor, ErbB-2

Share to Receptors, Somatomedin

Share to Trastuzumab

Source

Identifiers

PMID: 17371768

Genes

EGFR
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].PMID 17371768Read ↗

Resistance to Anti-HER2 Therapies in Breast CancerSemantic proximity Read ↗

Molecular aspects of breast cancer resistance to drugs (Review).Semantic proximity Read ↗

Mechanisms of resistance to HER2 target therapy.Semantic proximity Read ↗

HER2/PI3K/AKT pathway in HER2-positive breast cancer: A reviewSemantic proximity Read ↗

Unveiling the Molecular Mechanism of Trastuzumab Resistance in SKBR3 and BT474 Cell Lines for HER2 Positive Breast CancerSemantic proximity Read ↗

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy ResistanceSemantic proximity Read ↗

The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistanceSemantic proximity Read ↗

Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab ResistanceSemantic proximity Read ↗

Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2- Breast CancerSemantic proximity Read ↗

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast CancerSemantic proximity Read ↗

Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer.Semantic proximity Read ↗

New agents for endocrine resistance in breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.